Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants
Chutima Seree-aphinan, Kumutnart Chanprapaph, Ploysyne Rattanakaemakorn, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 17

Showing 17 citing articles:

COVID-19 Vaccines: Where Did We Stand at the End of 2023?
Kenneth Lundström
Viruses (2024) Vol. 16, Iss. 2, pp. 203-203
Open Access | Times Cited: 9
Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients
Chutima Seree-aphinan, Yanisa Ratanapokasatit, Poonkiat Suchonwanit, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis
Alvina Widhani, Anshari Saifuddin Hasibuan, Retia Rismawati, et al.
Vaccines (2023) Vol. 11, Iss. 9, pp. 1456-1456
Open Access | Times Cited: 10
Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine
Anna Pira, Jo Linda Sinagra, Francesco Moro, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 8
Immunogenicity, Effectiveness, and Safety of COVID-19 Vaccines among Patients with Immune-Mediated Dermatological Diseases: A Systematic Review and Meta-analysis
Sonphet Chirasuthat, Yanisa Ratanapokasatit, Kunlawat Thadanipon, et al.
Acta Dermato Venereologica (2024) Vol. 104, pp. adv40009-adv40009
Open Access | Times Cited: 2
A real-world prospective cohort study of immunogenicity and reactogenicity of ChAdOx1-S[recombinant] among patients with immune-mediated dermatological diseases
Kumutnart Chanprapaph, Chutima Seree-aphinan, Ploysyne Rattanakaemakorn, et al.
British Journal of Dermatology (2022) Vol. 188, Iss. 2, pp. 268-277
Closed Access | Times Cited: 8
Exacerbation of Autoimmune Bullous Diseases After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination: Is There Any Association?
Nika Kianfar, Shayan Dasdar, Ali Salehi Farid, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 7
Risk–benefit profiles associated with receiving Moderna COVID‐19 (mRNA‐1273) vaccine as an additional pre‐booster dose in immune‐mediated dermatologic disease patients with low SARS‐CoV‐2‐specific immunity following the primary series: A prospective cohort study
Chutima Seree-aphinan, Poonkiat Suchonwanit, Ploysyne Rattanakaemakorn, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 5
Closed Access | Times Cited: 3
Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by Durvalumab: A Case Report and Literature Review
Nathathai Pratumchart, Kumutnart Chanprapaph, Nuttapong Topibulpong, et al.
Clinical Cosmetic and Investigational Dermatology (2022) Vol. Volume 15, pp. 51-62
Open Access | Times Cited: 5
Immunogenicity of Intradermal Versus Intramuscular BNT162b2 COVID-19 Booster Vaccine in Patients with Immune-Mediated Dermatologic Diseases: A Non-Inferiority Randomized Controlled Trial
Chutima Seree-aphinan, Ploysyne Rattanakaemakorn, Poonkiat Suchonwanit, et al.
Vaccines (2024) Vol. 12, Iss. 1, pp. 73-73
Open Access
The Impact of Immune-Modifying Treatments for Skin Diseases on the Immune Response to COVID-19 Vaccines: a Narrative Review
Su-Yi Liew, Timothy Tree, Catherine Smith, et al.
Current Dermatology Reports (2022) Vol. 11, Iss. 4, pp. 263-288
Open Access | Times Cited: 3
Impaired neutralizing antibodies and preserved cellular immunogenicity against SARS-CoV-2 in systemic autoimmune rheumatic diseases
Porntip Intapiboon, Parichat Uae-areewongsa, Jomkwan Ongarj, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 3
Immunosuppressants in dermatology on vaccine immunogenicity: a prospective cohort study of pemphigus patients in the pandemic
Kun‐Lin Lu, Hua-En Lee, Chun‐Bing Chen, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
COVIDvaccine recommendations in dermatologic patients on immunosuppressive agents: Lessons learned from pandemic
Zeinab Aryanian, Kamran Balighi, Zeinab Mohseni Afshar, et al.
Journal of Cosmetic Dermatology (2022) Vol. 21, Iss. 12, pp. 6568-6573
Open Access | Times Cited: 2
Multiple COVID reinfections in a vaccinated psoriatic patient receiving adalimumab
Omid Zargari, Seyyede Zeinab Azimi
Journal of Dermatological Treatment (2022) Vol. 34, Iss. 1
Open Access | Times Cited: 1
Sars-cov-2-vaccine-inactivated-sinovac-biotech

Reactions Weekly (2023) Vol. 1962, Iss. 1, pp. 359-359
Closed Access
Impaired Neutralising Antibodies to SARS-CoV-2 Omicron BA.2 Variant and Preserved Cellular Immunogenicity Following Heterologous Prime-Boost Vaccination with an Inactivated Vaccine Followed by ChAdOx1-nCoV-19 in Patients with Systemic Autoimmune Rheumatic Diseases
Porntip Intapiboon, Parichat Uae-areewongsa, Jomkwan Ongarj, et al.
SSRN Electronic Journal (2022)
Closed Access
Page 1

Scroll to top